Get the Stockscreener App
1.50
4.46%
-0.07
NanoViricides Inc stock is traded at $1.50, with a volume of 162.38K.
It is down -4.46% in the last 24 hours and up +9.49% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.57
Open:
$1.55
24h Volume:
162.38K
Relative Volume:
1.12
Market Cap:
$23.88M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-2.1429
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
-16.20%
1M Performance:
+9.49%
6M Performance:
+10.29%
1Y Performance:
-38.27%
1-Day Range:
$1.48
$1.6149
1-Week Range:
$1.48
$1.9195
52-Week Range:
$0.94
$3.59
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.4861 | 23.79M | 0 | -8.29M | -6.47M | -0.70 |
|
ONC
Beone Medicines Ltd Adr
|
246.59 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.03 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.77 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.86 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
NanoViricides to Showcase Breakthrough Antiviral Platform at BIO International Convention - citybuzz -
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 - ACCESS Newswire
NanoViricides to present at BIO International Convention 2025 in Boston - Proactive financial news
NanoViricides president backs FDA's targeted COVID booster policy shift - Proactive Investors
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan - ACCESS Newswire
Small cap wrap: NanoViricides, Trust Stamp, NextSource, StickIt... - Proactive financial news
NanoViricides advances NV-387 antiviral program, eyes Phase II trials for Mpox - Proactive Investors
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in AfricaPhase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu - thederrick.com
NanoViricides: MPox ethics approval enables Phase 2 application - Proactive Investors
NanoViricides: Fiscal Q3 Earnings Snapshot - Huron Daily Tribune
Small cap wrap: atai, Black Swan Graphene, TNR Gold, NanoViricides... - Proactive financial news
NanoViricides progresses antiviral portfolio as measles and MPox threats rise - Proactive financial news
Measles Cases Are Increasing Globally; MPox Continues to Be a ThreatBroad-Spectrum Antiviral Drug Could Be the Solution - The Derrick
Small cap wrap: NanoViricides, Alvopetro, Polarean... - Proactive financial news
NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC - Proactive financial news
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo - The Derrick
Renaissance Technologies LLC Buys 30,800 Shares of NanoViricides, Inc. (NYSE:NNVC) - Defense World
NanoViricides to Present Innovative Antiviral Drug Research at D. Boral Capital Conference - citybuzz -
NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC - The Globe and Mail
Geode Capital Management LLC Acquires 31,956 Shares of NanoViricides, Inc. (NYSE:NNVC) - Defense World
NanoViricides Advances Broad-Spectrum Antiviral Drug for Measles Treatment - citybuzz -
NanoViricides advances measles drug development amid rising US cases | NYSE-A:NNVC - Proactive financial news
Press Release Distribution & PR Platform - ACCESS Newswire
Measles is Likely to Become EndemicNanoViricides Is Testing a Drug to Combat It - The Derrick
New research warns measles could become endemic again in the US as vaccination rates fall - Proactive financial news
"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market"Conclude Two Independent Research Reports on NanoViricides - ACCESS Newswire
Nanostructured Drug Market Projected for Significant Expansion by 2032 -Nanoviricides Inc, Ablynx NV, Pfizer - newstrail.com
Small cap wrap: Gunnison Copper, Ocean Power Technologies, NanoViricides... - Proactive financial news
NanoViricides evaluating antiviral drug NV-387 for measles treatment - Proactive financial news
Measles Outbreak Expands Begging for a Drug to Treat the InfectionNanoViricides Declares it is Ready to Fight the Outbreak - Lelezard
NanoViricides, Inc. Appoints Irach Taraporewala as the New CEO and Nominates to Serve as a Member of the Board of Directors - marketscreener.com
Nanostructured Drug Market Detailed In New Research Report 2025 | Nanoviricides Inc., Ablynx NV, Pfizer - newstrail.com
NanoViricides Provides an Update on Its Clinical Program and StrategyNV-387 Could be As Revolutionary as Antibiotics - ACCESS Newswire
NanoViricides unaffected by US tariff turmoil, says CFO - Proactive financial news
NNVC stock touches 52-week low at $1.02 amid market challenges - Investing.com Canada
NanoViricides unimpacted by tariffs; sees boost by changes at government agencies - Proactive Investors
NNVC stock touches 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):